Patients with bladder cancer in Scotland will be the first in the UK to claim access to maintenance treatment with Merck Serono and Pfizer's Bavencio, ahead of their counterparts in England
The UK drugs regulator has backed Merck KGaA's MET inhibitor for the treatment of some patients with non-small cell lung cancer under the early access to medicines scheme (EAMS).
Merck KGaA has forged a second partnership in the bioelectronics category in two weeks, teaming up with Innervia to develop neurostimulator devices for treating chronic diseases.